Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biofrontera Inc WT (BFRIW)

Biofrontera Inc WT (BFRIW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 37,320 K
  • Annual Income, $ -17,760 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/19/26 [AMC]
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0370 +68.65%
on 03/09/26
0.0700 -10.86%
on 02/25/26
+0.0123 (+24.55%)
since 02/11/26
3-Month
0.0370 +68.65%
on 03/09/26
0.0900 -30.67%
on 12/31/25
-0.0076 (-10.86%)
since 12/10/25
52-Week
0.0251 +148.61%
on 05/01/25
0.2770 -77.47%
on 07/25/25
+0.0044 (+7.59%)
since 03/10/25

Most Recent Stories

More News
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris 

• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”),...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansion Data to complement previously announced positive Phase 3 efficacy results on extremities, neck and...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz ® would be the first and only PDT photosensitizer indicated for the treatment of superficial...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz ® vs. vehicle gel (p

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

Fourth quarter results represent highest quarterly revenue in Company’s history Q4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz ® Full year 2025 revenues also expected...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

• Ameluz ® and RhodoLED ® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. • Assignment to Biofrontera...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz ® over treatment area of 240 cm 2 Completion of this study marks a key milestone...

BFRI : 0.8690 (+2.72%)
BFRIW : 0.0624 (-0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar